Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Failed French Drug Trial Hospitalizes Six Participants

By Drug Discovery Trends Editor | January 19, 2016

The French health ministry said on Friday that six volunteers taking part in a drug trial held by an unnamed pharmaceutical company were sent to the hospital, leaving one patient in a coma and the remainder critically ill.

The initial statement released by the French health ministry didn’t specify what the drug was or which company sponsored the trial, but The Guardian, in conjunction with Agence-France Press, reported that it was a Phase 1 clinical trial for an oral painkiller containing cannabinoids, for a trial run by a firm called Biotrial.

Biotrial is a laboratory based in Rennes, France. The company posted an update on their website acknowledging it had held a study for a sponsor in which trial participants experienced adverse events. The trial was “conducted in full compliance with the international regulations and Biotrial’s procedures were followed at every stage throughout the trial, in particular the emergency procedures for the transfer of subjects to the hospital,” according to the update.

Health Minister Marisol Touraine said all six volunteers were healthy before they took part in the study, which tested the “safety, tolerability, pharmacological profiles of this molecule,” according to her statement.

All trials for this drug have been suspended. Touraine held a press conference on Friday where she said Biotrial conducted the study on behalf of Portugal-based Bial, according to Reuters.

The drug being tested didn’t contain cannabis or any substance that was derived from cannabis either. 

The Associated Press (AP) reported on Sunday that one of the participants had died. The Renees University hospital where the volunteers were being treated didn’t identify the patient in its official statement, but the others still remain hospitalzed. 

Also, the AP writes that the hospital said it has contacted, “the 84 other volunteers exposed to the new painkiller. Ten of those volunteers underwent medical exams Saturday, but the hospital found no anomalies, the statement says. It said another five will have medical exams closer to their homes, but didn’t say whether the others are being monitored or tested.”


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE